Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Zepbound is the newest GLP-1 medication ... weight loss when combined with a well-balanced diet and exercise routine. In November 2023, the Food and Drug Administration (FDA) approved Zepbound ...

Insulin release: It triggers insulin production, lowering blood sugar and converting food to energy ... healthcare provider for a full list of side effects. Zepbound is a GLP-1 agonist ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

While the WHO decided not to recommend GLP-1 agonists for diabetes treatment in its 2023 Essential Medicines List (EML), it is likely ... public reforms such as improving food labelling and affordable ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...